Kaleido Biosciences, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kaleido Biosciences, Inc. (KLDO) operates as a clinical-stage biotechnology company that develops microbiome metabolic therapies (MMTs) designed to modulate the metabolic output of the human microbiome organ for treating diseases and improving health; its pipeline includes candidates such as KB195 for urea cycle disorders, KB174 for hepatic encephalopathy, KB295 for ulcerative colitis, and KB109 for COVID-19 and chronic obstructive pulmonary disease, alongside preclinical programs targeting multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company maintains collaboration agreements with the Institute Gustave Roussy, Washington University, and Janssen to advance its microbiome-focused research. Founded in 2015 by Geoffrey von Maltzahn and Noubar B. Afeyan and headquartered in Lexington, Massachusetts, Kaleido Biosciences previously raised over $165 million in private funding prior to its IPO and pursued clinical trials across rare genetic disorders, infectious diseases, and metabolic conditions. In recent major developments, the company discontinued its lead programs including KB109 following an FDA warning letter in 2022, terminated additional pipeline efforts such as those for COPD and ulcerative colitis, delisted from Nasdaq, wound down operations, and laid off remaining staff amid cash constraints and unsuccessful strategic sale efforts. As of 2025, Kaleido Biosciences trades on OTC markets at minimal share prices with no active development initiatives reported.
Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL)
Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR
Dear KLDO Stock Fans, Mark Your Calendars for April 28
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
ORIC Stock Plunges on Discontinuation of Oncology Candidate
Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress
Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?
Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now
Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates
Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround
Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021
Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference
Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates
Kaleido Biosciences Reports Second Quarter 2021 Financial Results
Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial
Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors